ePrivacy and GPDR Cookie Consent by TermsFeed Generator
×

Home

News

Contact

Seroprevalence of SARS-CoV-2 virus infection in employees in the health insurance sector

By
Biljana Mijović ,
Biljana Mijović

Faculty of Medicine Foca, University of East Sarajevo ,Lukavica ,Bosnia and Herzegovina

Dejan Bokonjić ,
Dejan Bokonjić

Faculty of Medicine, Foca, The Republic of Srpska, Bosnia and Herzegovina, University of East Sarajevo ,Lukavica ,Bosnia and Herzegovina

Dragana Puhalo-Sladoje ,
Dragana Puhalo-Sladoje

Faculty of Medicine, Foca, The Republic of Srpska, Bosnia and Herzegovina, University of East Sarajevo ,Lukavica ,Bosnia and Herzegovina

Dragan Spaić ,
Dragan Spaić

Faculty of Medicine, Foca, The Republic of Srpska, Bosnia and Herzegovina, University of East Sarajevo ,Lukavica ,Bosnia and Herzegovina

Jelena Vladičić-Mašić ,
Jelena Vladičić-Mašić

Faculty of Medicine, Foca, The Republic of Srpska, Bosnia and Herzegovina, University of East Sarajevo ,Lukavica ,Bosnia and Herzegovina

Anđela Mandić ,
Anđela Mandić

Faculty of Medicine, Foca, The Republic of Srpska, Bosnia and Herzegovina, University of East Sarajevo ,Lukavica ,Bosnia and Herzegovina

Srđan Mašić ,
Srđan Mašić

Faculty of Medicine, Foca, The Republic of Srpska, Bosnia and Herzegovina, University of East Sarajevo ,Lukavica ,Bosnia and Herzegovina

Abstract

Introduction. Serological testing for SARS-CoV-2 virus infection is a valuable method of estimating the extent of COVID-19 disease prevalence. The study aims to assess the seroprevalence of SARS-CoV-2 virus infection in a specific group of respondents employed in the health insurance sector, to determine the ratio of symptomatic and asymptomatic cases, as well as to examine susceptibility to COVID-19 in relation to the ABO blood group system. Methods. This research was conducted among 150 randomly selected employees from the health insurance sector of the Republic of Srpska. All respondents completed the survey, voluntary consent to participate, and had a blood sample taken. Serum samples were tested for the presence of SARS-CoV-2 specific IgG antibodies. Results. The seroprevalence of SARS-CoV-2 virus infection was 70.7%. Out of the 100 seropositive respondents, 48% had the presence of a symptom of COVID-19, while 52% had no symptoms of the disease in the period from 1 March 1 2020 until the day of testing. Examining the association between ABO blood group system and seropositivity in our study, we found that the highest seroprevalence of SARS-CoV-2 IgG antibodies among respondents was in blood group B (83.3%), followed by blood group AB (80.0%) and blood group A (75.0%), while the lowest seroprevalence was among respondents with blood group O (54.1%). Conclusion. Among employees in the health insurance sector, SARSCoV-2 seroprevalence of 70.7% was registered. Among respondents with a positive serological result on IgG, 52% were asymptomatic. The seroprevalence of SARS-CoV-2 virus infection is the lowest among subjects with blood group O.

Keywords

Citation

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.